Health Care Equipment

Morgan Keegan reiterates its Outperform rating and $26 target price on Masimo Corporation (NASDAQ: MASI), reflecting a still-favorable risk/reward ratio for the company. Morgan Keegan says, "Masimo's 2011 stock underperformance was driven by issues that negatively impacted financial results,...

Brean Murray Carret maintains its rating of Buy on Masimo Corporation (NASDAQ: MASI) and lowers its price target to $24 from $27 as bar seems low for Q4. Brean Murray Carret says, "After several miscues during 2011, management guided Q4 to assume only 10% growth, which reflected a very cautious...

Masimo (NASDAQ: MASI) today announced FDA 510(k) clearance and full market commercial launch of the Masimo Pronto-7®—a palm-sized handheld device designed for quick and easy noninvasive spot-checking of total hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index.

Shares of MAKO Surgical (NASDAQ: MAKO) are higher on the session by 9.28%, currently trading at $31.45. The stock has been moving largely higher over the past five weeks and is currently trading above the 50-day moving average. Options traders are focusing on calls today. The strike seeing the...

MAKO Surgical Corp. (Nasdaq: MAKO) today announced its selected operating results for its fourth quarter and for the year ended December 31, 2011 and provided 2012 annual guidance in anticipation of its business update presentation at the 30th Annual J.P. Morgan Healthcare Conference at the Westin...

Shares of MAKO Surgical (NASDAQ: MAKO) are having much strength in early trading today. At one point, MAKO was up over 13%. Boutique firm, Summer Street, upgraded MAKO to a Buy, from a Neutral rating. Currently, shares of MAKO Surgical are trading over 11% higher at $28.19.

Summer Street has upgraded MAKO Surgical (NASDAQ: MAKO) from Neutral to Buy.

JP Morgan reiterates its Neutral rating on Mako Surgical (NASDAQ: MAKO) and lowers its price target to $32 from $37 as systems sold in the third quarter missed expectations and fuel concerns related to HMA contract draw-down. JP Morgan comments, "Systems sold in 3Q11 fell one short of Street...

JP Morgan has lowered the price target on Mako Surgical (NASDAQ: MAKO) from $37 to $32 and maintains its Neutral rating.

Masimo (NASDAQ: MASI) announced today that a new clinical study evaluating Masimo Acoustic Respiration Rate was presented at the New York State Society of Anesthesiologists Annual Post Graduate Assembly Meeting in New York City. The new study, presented at the 2011 NYPGA, highlights the...

In a note out today, PiperJaffray reiterated an overweight rating and $31 price target on medical device maker Masimo (Nasdaq: MASI). That price target implies more than 50% upside from where the shares currently reside. Masimo recently participated in PiperJaffray's annual healthcare conference...

According to Bank of America, Masimo (NASDAQ: MASI) coverage is initiated with an Underperform rating and $19 price target. Bank of America said that it is launching coverage of Masimo (MASI) at Underperform with a $19 PO. “Based on a combination of Masimo's standard pulse oximetry product and...

Bank of America has initiated coverage on Masimo Corporation (NASDAQ: MASI) with an Underperform rating and $19 price objective.

In a published research note, Goldman Sachs reiterated it Buy rating on MAKO Surgical Corp. (NASDAQ: MAKO) as knee utilization continues rise and hip utilization exceeds expectations. Goldman states, “MAKO Surgical reported 3Q2011 revenue of $20.0mn, 1.2% above our estimate and 3.2% above the...

J.P. Morgan Chase & Co. is out with a research report on Mako Surgical (NASDAQ: MAKO) and it is raising its price target to $37 from $28, but is keeping its Neutral rating after it reported earnings. In a note to clients, J.P. Morgan Chase & Co. writes, "Mako reported 3Q results Wednesday...